GlassScriptPhysician profile
Kathleen J Smith
NPI 1396916219
$57,108.78
in general payments reported to CMS, 2019-2025
32 companies · $4,700 in 2025
The $4,700 reported for 2025 was more than what 96% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $8,108 · 2021: $4,744 · 2022: $18K · 2023: $3,486 · 2024: $5,451 · 2025: $4,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,039 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,398 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,038.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,397.70 |
| Education | $200.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,454.87 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $6,833.92 | 2019-2025 | Cosentyx |
| Regeneron Healthcare Solutions, INC. | $1,781.34 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,515.82 | 2019-2025 | |
| Pfizer INC. | $1,254.95 | 2019-2025 | |
| Lilly USA, LLC | $1,192.79 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,009.95 | 2019-2025 | Siliq, Targretin, Duobrii |
| Janssen Biotech, INC. | $885.02 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $726.18 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $493.85 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $388.75 | 2019-2025 | Winlevi |
| Dermavant Sciences, INC. | $233.24 | 2023-2024 | Vtama |
| Incyte Corporation | $162.00 | 2021-2025 | Opzelura |
| Amgen INC. | $136.14 | 2021-2023 | Otezla, Enbrel |
| Organon LLC | $130.93 | 2023-2025 | Hadlima, Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $106.56 | 2019 | |
| Sandoz INC. | $104.09 | 2023-2025 | Hyrimoz |
| Helsinn Therapeutics (U.S.), INC. | $79.27 | 2019-2022 | |
| Phadia US INC. | $67.71 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $64.01 | 2024-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $63.79 | 2019-2021 | |
| Genentech USA, INC. | $63.28 | 2021-2022 | |
| Galderma Laboratories, L.P. | $53.77 | 2024-2025 | Nemluvio |
| Biocon Biologics INC | $47.97 | 2024 | Hulio |
| Mayne Pharma Commercial LLC | $47.49 | 2021-2022 | |
| Prugen, INC. Pharmaceuticals | $43.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.30 | 2023-2024 | Spevigo |
| Lnhc, INC | $39.32 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $25.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.19 | 2022 | |
| Fidia Pharma USA INC. | $20.35 | 2024 | Hyalgan, Triluron, Hymovis |
| Almirall LLC | $17.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.